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DOI: 10.1002/jcp.22111Several studies have highlighted the importance of intercellular
communication mechanisms involving the release of different
types of vesicles into the extracellular space by cultured cells or
organized tissues (Hugel et al., 2005; Cocucci et al., 2009). Some
types of vesicles, which are distinct from the exosomes released
upon exocytosis of multivesicular bodies, bud directly from the
plasma membrane (Cocucci et al., 2009). These spherical
structures have proteins and lipids similar to those present in
the plasma membrane of the cells from which they originate and
their content differs depending on the cell type, indicating the
specificity of the process (Beaudoin and Grondin, 1991).
Reports have shown that vesicles independent of their origin
can transfer biological information between cells, acting as
vectors of signaling molecules (Martı́nez et al., 2005). Vesicle
release from cells has been described under both physiological
(Beaudoin and Grondin, 1991; Taraboletti et al., 2002) and
physiopathological conditions (Freyssinet, 2003), and may also
take place in tumor cells (Taverna et al., 2003; Millimaggi et al.,
2006; Taraboletti et al., 2006). The mechanisms governing
vesicle production and release are far from being clearly
understood. However, it is known that cholesterol-rich
microdomains of the plasma membrane are involved in vesicle
production (Pilzer et al., 2005), and supplementation of culture
medium with serum as well Ca2þ ions may be required to
stimulate vesicle shedding in vitro (Taraboletti et al., 2002;
Taverna et al., 2003; Pilzer et al., 2005; Ratajczak et al., 2006a).
Released vesicles may remain near the cells of origin, but are
also found in the blood and other biological fluids, indicating that
they can transport their cargo in an environmentally protected
form and act at a distance (Martı́nez et al., 2005). Vesicle cargo
may be delivered to other cells, and recent reports have
demonstrated microRNA transfer from embryonic stem cell to
mouse embryonic fibroblasts via microvesicles, indicating a
regulated transfer process (Yuan et al., 2009). Embryonic stem
cells are also capable of shedding microvesicles containing 2 0 1 0 W I L E Y - L I S S , I N C .mRNAs and ligands (Ratajczak et al., 2006b), indicating that this
process can be a mechanism for paracrine signaling. Against this
backdrop, we explored the possibility that mouse
mesoangioblast stem cells release vesicles containing signaling
molecules that may have relevant biological functions. Mouse
mesoangioblasts are vessel-associated multipotent stem cells
that are capable of differentiating into different mesodermal cell
types (Minasi et al., 2002). An important property of
mesoangioblasts is their ability to cross the endothelial barrier;
when injected into the mouse circulation for repair therapy,
they localize to experimentally damaged tissues, attracted by
high mobility group box-1 protein (HMGB-1) released from
necrotic cells (Palumbo et al., 2004; Galvez et al., 2006). Indeed,
the capacity of intra-arterially delivered mesoangioblast to
reduce the severity of muscular dystrophy in mice and dogs, and
ameliorate myocardial damage in infarcted mouse hearts has
been demonstrated (Sampaolesi et al., 2003, 2006; Galli et al.,
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mesoangioblasts express molecules such as fibroblast growth
factor-2 (FGF-2), HGF, and IGF-1 that confer on themselves
properties important in repairing damaged tissues. In the
current study, we found that mouse mesoangioblasts produce
and release plasma membrane vesicles that contain proteins
such as FGF-2 and matrix metalloproteinase (MMP-9) that have
proved important in cell therapy. Because these molecules are
encapsulated, they are initially protected from the environment
when released into the extracellular space.
Materials and Methods
Cell culture and treatment
Mouse A6 stem cells were grown on collagen I-coated plates in
Dulbecco’s modified Eagle medium (DMEM; Invitrogen, Carlsbad,
CA) with or without 10% fetal bovine serum (as indicated in the
text) in a humidified 5% CO2 atmosphere at 378C. For experiments
with lower oxygen tension, cells were grown as previously
described (Wright and Shay, 2006). For pharmacological
experiments, cells were treated with nocodazole, a drug for
microtubule depolymerization, (Sigma-Aldrich, St. Louis, MO) for
18 (2.5mM) or 3 h (3mM); cytochalasin B, a drug which impairs
actin microfilaments polymerization and elongation by capping
filament plus ends (Sigma) for 18 (2mM) or 3 h (4mM); and methyl-
b cyclodextrin (Sigma) for 6 h (2.5 mM). HT-1080 cells were grown
in RPMI (Invitrogen) medium supplemented with 10% fetal bovine
serum in a humidified 5% CO2 atmosphere at 378C.
Three-dimensional collagen gel matrix culture
Cells were resuspended in culture medium containing 0.65 M
NaHCO3. One volume of acid-soluble type-I collagen solution was
mixed with one volume of A6 cell suspension. A 100-ml aliquot of
this solution was plated onto 3-mm diameter dishes and
immediately warmed to 378C to form a gel. After polymerization,
each gel was overlaid with 200ml of medium.
Phalloidin staining of collagen gels
Collagen gels were fixed in 1.85% formaldehyde for 5 min at room
temperature and then washed three times with PBS (68 mM NaCl,
1.3 mM KCl, 4 mM Na2HPO4, 0.4 mM CaCl2, 0.2 mM MgCl2,
0.8 mM KH2PO4) for 5 min each. Gels were incubated with
fluorescein-conjugated phalloidin in 1 PBS (1:200 dilution) for 1 h
at 378C. Collagen gels were coverslip-mounted with DABCO
(diazabicyclo 2, 2, 2 octane; Sigma1). Fluorescent cells were
analyzed using an Olympus BX50 microscope equipped with a
Nikon sight DS-U1.
Purification of vesicles from medium
Vesicles were purified from medium as described (Dolo et al.,
1994). Briefly, medium conditioned by subconfluent healthy cells
for different lengths of time was centrifuged at 2,000g for 10 min
and at 4,000g for 15 min. The supernatant was ultracentrifuged at
105,000g for 90 min, and pelleted vesicles were resuspended in
PBS. Protein content of isolated vesicles was determined using the
Bradford microassay method (Sigma) with bovine serum albumin as
a standard.
Acetylcholinesterase assay
Vesicle release was quantified by measuring the activity of
acetylcholinesterase (AchE). Briefly, vesicles (5ml) were
suspended in PBS (95ml) and incubated with 1.25 mM
acetylthiocholine chloride (Sigma) and 0.1 mM 5,50-dithio-bis
(2-nitrobenzoic acid) (3,30-6; Sigma). PBS was then added to a final
volume of 1 ml, and the change in absorbance at 412 nm was
monitored every 5 min for 20 min.JOURNAL OF CELLULAR PHYSIOLOGYTrypan blue dye exclusion
Cell viability was measured by staining cells with trypan blue dye
and then counting, as described elsewhere (McCloskey et al.,
1998).
Preparation of protein extracts
Protein extracts were prepared as previously described (Geraci
et al., 2006). Protein concentration in extracts was determined
using the Bradford microassay method (Sigma) with bovine serum
albumin as a standard.
Coomassie staining
Whole-cell extract and vesicle proteins were separated by SDS–
PAGE on 10% gels. Gels were stained with Coomassie Blue as
described previously (Barnouin, 2004).
Western blots
Whole-cell extract and vesicle proteins were separated by SDS–
PAGE on 10% gels and transferred to an ECL-Hybond membrane
(Amersham Biosciences, Piscataway, NJ) using a mini-electroblot
apparatus (Biorad, Hercules, CA). After blocking for 2 h in TBST
buffer (10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.2% Tween-20)
containing 5% non-fat dry milk, membranes were incubated
overnight with the following antibodies: mouse polyclonal
anti-actin (1:800 dilution; Neomarkers, Fremont, CA), mouse
monoclonal anti-b-tubulin (1:400 dilution; Sigma), rabbit polyclonal
anti-filamin (1:200 dilution; Santa Cruz, Santa Cruz, CA), mouse
monoclonal anti-VE cadherin (1:200 dilution; R&D Systems,
Minneapolis, MN), rabbit polyclonal anti caveolin-1 (1:200
dilution; Sigma), rabbit polyclonal anti-sphingosine kinase-1
(SphK-1, 1:100 dilution; Abgent, Inc., San Diego, CA). Alkaline
phosphatase-conjugated anti-rabbit and anti-mouse (1:5,000
dilution; Promega Inc., Madison, WI) antibodies were used as
secondary antibodies. Horseradish peroxidase-conjugated anti-
rabbit (1:5,000 dilution; Promega) antibody was used as secondary
antibodies for filamine.
GM-1 ganglioside dot-blot assays
A6 cells and vesicles were incubated with HRP-conjugated cholera
toxin subunit B (dilution 1: 500; Sigma) in PBS for 1 h at 08C. After
washing twice with PBS, cells were lysed with 1% Triton X-100 for
30 min at 08C, whereas vesicles were resuspended in PBS. Cell
lysates and vesicles (30mg) were transferred to ECL-Hybond
(Amersham) membranes. The membranes were then dried,
washed with PBS and developed using enhanced
chemiluminescence.
Gelatin zymography
Samples were electrophoresed on 7.5% SDS–PAGE containing
6 mg/ml gelatin type B (Sigma). Vesicles samples were diluted in
SDS–PAGE sample buffer under non-reducing conditions without
heating. After electrophoresis, gels were washed in 2.5% Triton
X-100, incubated overnight at 378C in buffer containing 50 mM
Tris–HCl, pH 7.5, 2 mM CaCl2 and 1.5% Triton X-100, or in buffer
containing 50 mM Tris–HCl, pH 7.5, 2 mM EDTA and 1.5% Triton
X-100, and then stained with Comassie Blue R 250 (Sigma) for 48 h.
Vesicles samples from HT-1080 cells were used as a reference
standard for pro-MMP-9, pro-MMP-2, MMP-9, and MMP-2
(Ginestra et al., 1997). Gelatinase activity was visualized as a clear
zone against a blue background, indicating proteolysis of substrate.
Vesicle immunofluorescence
Isolated vesicles were fixed with 3.7% paraformaldehyde for 40 min
in culture medium and then centrifuged at 2,700g for 5 min. Pelleted
vesicles were washed sequentially with PBS and PBS containing
0.1 M glycine, and then cytocentrifuged onto poly L-lysine-coated
slides at 1,000g for 5 min. Slide-mounted vesicles were
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with PBS (5 min each), and then incubated with mouse monoclonal
anti-FGF2 antibody solution (1:50 dilution; Upstate Lake Placid,
NY) overnight at 48C or with FITC-conjugated cholera toxin
subunit B (10mg/ml; Sigma) for 1 h. After washing, slides were
incubated with FITC-conjugated anti-mouse secondary antibodies
(1:400 dilution; Amersham) After a final wash, slides were
coverslip-mounted with DABCO. Fluorescent vesicles were
analyzed using an Olympus BX50 microscope equipped with a
Nikon sight DS-U1.
Assay for urokinase plasminogen activity (uPA) activity
GM7373 cells (1.75 106), plated at a density of 7 104 cells/cm2,
were grown for 28 h in a serum-free medium. After that cells were
incubated for 18–24 h with A6-vesicle. After removing the culture
supernatant, the cells were washed twice with PBS, scraped with a
rubber policeman, and then collected by centrifugation at 800g for
10 min at 48C. Cells were lysed, protein concentration was
measured by the Bradford method, and cell extracts (30mg
proteins) were separated by electrophoresis on 7.5% SDS–PAGE.
Zymography was performed as previously described (Vassalli et al.,
1984); overlay gels contained 3% non-fat dry milk and 40mg/ml
bovine plasminogen (Sigma). Densitometric analysis of the lysis
bands was performed using Science 1D Image Analyzer software
(Eastman Kodak Co, Rochester, NY). White bands in images
indicative of caseinolysis were converted to dark bands to better
display the activity. Neutralizing anti-FGF2 (Upstate
Biotechnology), mouse monoclonal anti-b-tubulin (Sigma) and
mouse monoclonal anti-Hsp70/Hsc70 (Sigma) antibodies were
used in this assay.
Flow cytometry
Isolated vesicles were diluted in 1 ml of filtered PBS containing flow
cytometer calibration polystyrene microspheres with the following
diameters: 1.0, 2.0, 4.0, 6.0mm (Invitrogen) and then analyzed on a
BD FACSCanto (Franklin Lakes, NJ) for forward and 908 side
scatter (SS). Forward scatter (FS) and SS parameters were plotted
on logarithmic scales to best cover a wide size range.
Results
Mesoangioblast vesicle production and vesicle
characterization
To explore the possibility that mouse mesoangioblasts release
proteins into the extracellular space through a vesicle shedding
process as other cell types do (Cocucci et al., 2009), we
cultured the A6 mesoangioblast clone in three-dimensional
collagen gels (Noble, 1987; D’Agostino et al., 2006). Staining
with fluorescein conjugated-phalloidin showed the presence ofFig. 1. Membrane vesicle shedding by mesoangioblasts. A: Fluorescence
in three-dimensional collagen gels in the presence of serum. Vesicles are s
C:Cells cultured in three-dimensional collagen gelswithout serum. Insets, a
Many cells were examined and a representative cell is shown. Scale bars:
JOURNAL OF CELLULAR PHYSIOLOGYvesicle structures near the plasma membrane of cells (Fig. 1A).
Mesoangioblasts also produced vesicles under low-oxygen
tension; that is, under conditions more similar to those of
mammalian tissues (Wright and Shay, 2006; Fig. 1B). It has been
suggested that the high-oxygen content used routinely in cell
culture may be somewhat of a stress on primary cells. However,
our observations preclude the possibility that transfer of
mesoangioblasts from aortic tissue (low-oxygen tension) to cell
culture (higher oxygen tension) induces vesicle production as a
result of hyperoxygen stress. In contrast to other cells that shed
vesicles only in complete medium (Dolo et al., 1994; Taverna
et al., 2003), A6 mesoangioblasts also produced vesicles in
serum-free medium (Fig. 1C).
Vesicles were studied by recovering them from conditioned
medium at different times after medium replacement, as
described (Galli et al., 1993; Dolo et al., 1994). The protein
content of the vesicle pellet reached a maximal level within the
first 3 h, after which the level decreased to a lower value and
remained constant (Fig. 2A). The stability of vesicles was
assessed by isolating cell-conditioned medium and analyzing
vesicle amounts at different times. As shown in
Figure 2B, vesicles released by A6 cells are not stable; thus, the
constant level observed in the shedding curve (Fig. 2A)
corresponds to a steady state that reflects vesicle production
and turnover. Vesicle shedding in serum-free medium followed
the same trend, but the level of shedding was much lower
(Fig. 2A). Flow cytometry assays showed that A6 vesicles vary in
size, but are 1mm in diameter (Fig. 2C), a size that excludes
the possibility that these vesicles are exosomes (Cocucci et al.,
2009).
Vesicle shedding requires integrity of the tubulin
cytoskeleton and raft microdomains
We next examined whether disruption of cytoskeletal
structures affects A6 mesoangioblast vesicle shedding. A6 cells
treated with cytochalasin B showed an altered round shape (not
shown), but the treatment did not affect vesicle production
(Fig. 3). In contrast, nocodazole treatment reduced vesicle
shedding by 30% (Fig. 3). It has recently been suggested that
laterally mobile lipid rafts in the plasma membrane may sort into
curved, cholesterol-rich membrane regions (Stein and Luzio,
1991; Del Conde et al., 2005; Hägerstrand et al., 2006). To
determine whether disrupting the integrity of these
cholesterol-rich microdomains affects A6 cell vesicle shedding,
we investigated vesicle release after methyl-b-cyclodextrine
(MBC) treatment, which inhibits raft organization. As shown in
Figure 3, MBC treatment reduced vesicle release to 55% of
control levels, indicating the involvement of these plasma
membrane lipid structures in vesicle shedding. Cell viability,observation of FITC-phalloidin labeled mesoangioblasts cultured
hown near the cell. B: Same as in (A), but in low-oxygen tension (8%).
higher magnificationof the picture depicted in panelsA,B, C(square).
10mm.
Fig. 2. Timecourseofvesiclesheddingandvesiclestability inmesoangioblast cells.A:Timecourseofvesicleshedding.Proteincontentofvesicles
recovered from medium conditioned by subconfluent healthy A6 cells at 1, 2, 3, 6, 14, 24, and 48 h. B: Shed-vesicle stability in mesoangioblast cells
wasdeterminedbymeasuringtheproteincontentofthevesiclepelletsrecoveredfrommediumconditionedbyA6cells for3 handincubatedat37-
Cfor6,9,24,and48 h.C:Flowcytometryanalysisof isolatedmesoangioblastvesicles.Data fromoneexperimentrepresentativeof three.SSC,side
scatter; FSC, forward scatter. Squares indicate calibration polystyrene microspheres with the following diameters: 1.0, 2.0, 4.0, and 6.0mm.
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by treatments (<3% dead cells), suggesting that nocodazole and
MBC-induced reduction in vesicle shedding was not due to a
generalized cytotoxic effect of the drugs.Fig. 3. Effect of cytochalasine B, nocodazole and methyl-b-
cyclodextrin treatment on vesicle shedding. Cells were incubated in
the presence of cytochalasine B, nocodazole, and methyl-b-
cyclodextrin as described in the ‘‘Materials and Methods.’’ Vesicles
were collected from the cultured medium and quantified by
measuring AchE activity. Each bar is the mean W SEM of three
independent experiments. Significance was calculated using
Student’s t-test, and P-values versus control of <0.0010 (M) and <0.01
(MM) are indicated.
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An electrophoretic analysis of vesicle protein content revealed
a complex pattern (Fig. 4A), consistent with previously
reported content analyses of vesicles shed from other cell types
(Hegmans et al., 2004). A comparison of the whole-cell and
vesicle protein patterns showed that the protein composition
of the vesicle is different from that of the cell as a whole
(Fig. 4A).
As a first step in the characterization of vesicle structure, we
investigated whether vesicles contain structural proteins that
are part of the cell cortex. Immunoblot analyses of vesicle
lysates showed the presence of actin (Fig. 4B), as already
highlighted by phalloidine fluorescent images (see Fig. 1A).
Filamin, a cytoskeletal protein that cross-links actin fibers, was
also present as were traces ofb-tubulin (Fig. 4B). Both actin and
filamin are important constituents of the cell cortex.
We also explored the presence of proteins characteristic of
the plasma membrane. Immunoblots showed that vesicles
contained VE-cadherin protein (Fig. 4B), consistent with
previous reports that VE-cadherin is expressed at the mRNA
level in A6 mesoangioblasts (De Angelis et al., 1999; Minasi et al.,
2002). This protein, which is essential for cell–cell adhesion,
is also involved in proliferative processes, but its role in
mesoangioblasts remains unexplored.
Because MBC-mediated membrane disruption induced a
significant decrease in vesicle shedding, we investigated
whether lipid rafts are also constituents of vesicles. To this end,
we probed for the presence of two raft markers, caveolin-1 and
Fig. 4. Comparison of protein’s pattern in A6 mesoangioblast cells and in shed vesicles. A: Separation of A6 lysates and A6 cell-derived vesicle
proteinson8%SDS–PAGE.Upperpanel:A6lysates;LowerPanel:membranevesicles.Profilesofdensitometricanalysisareshown.B:Immunoblot
assays of protein lysates: A6 cells (left) and membrane vesicles (right). Protein lysates were incubated using antibodies against actin, filamin,
tubulin, caveolin-1, VE-cadherin, SphK-1. Dot-blot assay with HRP cholera toxin B subunit for GM-I ganglioside. C: Cytocentrifuged isolated
vesicles, staining with FITC-conjugated cholera toxin B subunit. D: Cells cultured in three-dimensional collagen gels, labeled with fluorescent
cholera toxin B subunit. Scale bars: 10mm.
148 C A N D E L A E T A L .GM-1 ganglioside (Wang and Paller, 2006), by immunoblot and
dot-blot, respectively. As shown in Figure 4B, both lipid raft
markers were present in isolated vesicles. The presence
of GM-1 on mesoangioblasts (Fig. 4D) and isolated,
cytocentrifuged vesicles (Fig. 4C) was further confirmed by
fluorescence staining with the cholera toxin B subunit, which
binds GM-1. This finding indicates that raft microdomains are
constituents of vesicles and accounts for the ability of
MBC-mediated lipid raft disruption to reduce vesicle shedding.
Other molecules known to be produced by mesoangioblasts,
such as SphK-1 (Donati et al., 2009), were not present in vesicle
lysates at levels detectable by the assay used (Fig. 4B) indicating
that protein release through vesicles is a regulated process.
Vesicle proteins with extracellular functions
Injection of tendon fibroblasts engineered to express MMP-9
metalloproteinase into dystrophic mice has recently been
shown to reduce collagen deposition (Gargioli et al., 2008;
Lolmede et al., 2009), and mesoangioblasts have been reported
to be effective in repairing damaged tissues (Sampaolesi et al.,JOURNAL OF CELLULAR PHYSIOLOGY2003; Galli et al., 2005). To determine whether
mesoangioblasts synthesize and secrete active
metalloproteinases, we analyzed shed vesicles using
zymography. As shown in Figure 5 (lane 1), zymography
revealed the presence of two metalloproteinases, MMP-9 and
MMP-2, in extracts of mesoangioblast vesicles; both were
present in their activated form, as shown by bands of 79 and
58 kDa, respectively (Fig. 5). HT1080 vesicles were used as a
molecular mass standard (Fig. 5 lane 2), as demonstrated
(Ginestra et al., 1997). Zymography further indicated that pro-
MMP-2 (63 kDa) and pro-MMP-9 (91 kDa) are also released. In
the presence of EDTA, which blocks the metalloproteinase
activity, no bands were visible (data not shown). Some previous
studies in different cultured cell lines demonstrated cell capacity
to release MMP into conditioned medium through vesicle
shedding (Chavez-Muñoz et al., 2009), but it is the first time that
this mechanism has been observed for stem cells. These findings
are important in the context of mesoangioblast therapy,
suggesting that the action of these MMPs may lead to a
reduction in collagen deposition as observed when engineered
fibroblasts are injected in dystrophic mice (Gargioli et al., 2008).
Fig. 5. Gelatine zymography of vesicle-associated gelatinase.
Vesicles were purified from cell-conditioned medium containing 10%
FBS and analyzed by gelatine zymography as described in ‘‘Materials
and Methods.’’ Lane 1: vesicle lysates from mesoangioblasts;
Lane 2: vesicle lysates from HT1080 cells. Sizes are indicated in kDa.
Arrows indicate the proMMP9 (91 kDa) and its activated form
(79 kDa), the proMMP2 (63 kDa) and its activated form (58 kDa).
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FGF-2. There are two types of FGF-2: one type has a high
molecular mass and contains a classical N-terminal nuclear
localization signal, and the other is a low molecular mass type.
This latter isoform, which lacks a detectable secretion signal
sequence is known to be released through a mechanism
independent of the endoplasmic reticulum/Golgi pathway. To
determine whether FGF-2 is released into the extracellular
milieu through membrane vesicles, as is the case in other cell
types (Taverna et al., 2008), we analyzed isolated vesicles using
immunofluorescence. As shown in Figure 6, purified and
cytocentrifuged vesicles do contain FGF-2, indicating that
FGF-2 is indeed exported outside the cell through shed vesicles.
To assess the biological significance of vesicle-associated FGF-2,
we sought to verify whether mesoangioblast vesicles were
capable of delivering FGF-2 to endothelial cells and activate
downstream signaling. To accomplish this, we incubated
GM7373 endothelial cells with vesicles purified from
mesoangioblast-conditioned medium and assayed them for uPA
production, a characteristic response to FGF-2 signaling.Fig. 6. A6 shed vesicles contain FGF-2. A: Negative control, of
isolated and cytocentrifuged vesicles without anti-FGF2 antibodies.
B: Immunofluorescence of isolated and cytocentrifuged vesicles using
anti-FGF-2 antibody. Scale bar: 10mm. A: Immunofluorescence of
isolated and cytocentrifuged vesicles incubated only with the
secondary antibody as negative control. B: Immunofluorescence of
isolated and cytocentrifuged vesicles using anti-FGF-2 antibody. Scale
bar: 10mm. [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
JOURNAL OF CELLULAR PHYSIOLOGYCasein/plasminogen zymography of GM7373 cell extracts
showed that GM7373 cell-associated uPA activity was
increased by mesoangioblast vesicles in a dose-dependent
manner (Fig. 7A). To confirm that this effect was due to FGF-2
associated with vesicles and not to other vesicle contents, we
incubated GM7373 cells with both vesicles and a neutralizing
anti-FGF2 antibody. These assays showed that the anti-FGF-2
antibody blocked uPA production, indicating that the response
is, in fact, attributable to FGF-2 and not to some other
molecules contained within vesicles (Fig. 7B). In fact, non-
specific antibodies (anti-Hsp70/Hsc70 or anti-b tubulin) had no
effect on uPA activation.
This is the first demonstration that FGF-2 produced by
mesoangioblasts is exported into the extracellular milieu by
vesicles and serves as an active signal molecule capable of
activating uPA production in endothelial cells.
Discussion
In the present study, we showed that FGF-2 and the
metalloproteinases, MMP-9 and MMP-2—all factors important
for mesoangioblast biological function—are enclosed within
vesicular structures and released in an active form into the
extracellular space. A comparison of vesicle release and stability
curves revealed a process of continuous vesicle production and
turnover. The stability curve also indicated that vesicles are
stable in the culture medium for several hours, and therefore
their contents could be preserved in the extracellular space for
some period of time. This is supported by the presence in the
vesicles plasma membrane of lipid rafts, which may confer some
stiffness to these structures. The integrity of lipid rafts is
required for vesicle production, as shown by the fact that
A6 cell treatment with MBC, which disrupts rafts, decreases
the production of vesicles. The presence of the cytoskeletal
proteins, actin, and filamin, may reinforce the vesicles’
round shape. Importantly, the presence of GM-1 ganglioside
and VE-cadherin in A6 vesicles implies that the vesicles may be
generated from the plasma membrane. Mesoangioblast vesicle
production occurred even in the absence of serum, albeit at
very low levels relative to that observed in fully supplemented
medium. In contrast, the presence of serum in the culture
medium is absolutely required for vesicle production in other
cell types, such as endothelial cells and cancer cells (Taraboletti
et al., 2002; Taverna et al., 2003; Millimaggi et al., 2006).
Mesoangioblasts are a population of stem cells characterized
by the ability to migrate in vivo to sources of inflammation in
response to HMGB-1 released into the extracellular milieu
from necrotic cells (Palumbo et al., 2004; Galvez et al., 2006).
These cells have been shown to reduce the severity of muscular
dystrophy when delivered intra-arterially in dystrophic mice or
dogs (Sampaolesi et al., 2003, 2006), and to ameliorate
myocardial damage in infarcted mouse hearts (Galli et al., 2005).
An analysis of gene expression has revealed that
mesoangioblasts express growth factors, including FGF-2, that
prevent cardiomyocyte apoptosis and stimulate proliferation of
smooth muscle cells in newly formed vessels (Galli et al., 2005).
However, the mechanism governing secretion of FGF-2, which
lacks a detectable secretion signal sequence, has remained
poorly understood. Our current findings shed light on this
mechanism, demonstrating that, in culture, mesoangioblasts
release vesicles containing FGF-2 into the extracellular space.
That this FGF-2 is present in an active form is demonstrated by
its ability to induce synthesis of uPA in endothelial cells. It is
interesting that this growth factor is released from these stem
cells in a relatively protected structure.
Notably, the vesicles produced by A6 cells also contained the
activated form of MMP-2 and MMP-9. Cossu and colleagues
have shown that MMP-9, when expressed by modified tendon
fibroblasts, restores vascular networks and reduces the
Fig. 7. Induction of uPA activity in GM7373 cells by FGF-2 contained in mesoangioblast vesicles. A: Zymographic assay to measure the uPA
activity in GM7373 cells incubated with 0, 20, or 40mg of A6 mesoangioblast vesicles (lanes 1, 2, 3, respectively). B: Zymographic assay to measure
the uPA activity of: Lane 1: uPA activity of untreated GM7373 cells; Lane 2: uPA activity of GM7373 cells growing in the presence of 2.5mg of
inhibitory anti-FGF2 monoclonal antibodies; Lane 3: uPA activity of GM7373 cells growing in the presence of mesoangioblast vesicles R2.5mg of
inhibitory anti-FGF2 monoclonal antibodies; Lane 4: uPA activity of GM7373 cells growing in the presence of mesoangioblast vesicles R2.5mg of
anti-tubulin-bantibodies; Lane 5: uPA activity of GM7373 cells growing in the presence of mesoangioblastvesicles; Lane 6: uPA activity of GM7373
cells growing in the presence of mesoangioblast vesicles R2.5mg of anti-Hsp/Hsc70 antibodies. (A(, B() These data represents densitometric value
of uPA activity expressed in arbitrary units, considering 100 the basal uPA activity.
150 C A N D E L A E T A L .deposition of collagen that occurs in dystrophic muscles of aged
mice, and thereby improves the effectiveness of subsequent
mesoangioblast transplantation therapy (Gargioli et al., 2008).
Moreover, they found that MMP-9 secreted by polarized
macrophages, together with HMGB-1 and TNF-a, affects
mesoangioblast migration (Lolmede et al., 2009). Thus, the
finding that mesoangioblasts themselves produce and release
active MMP-9 and MMP-2 through vesicle production could
explain the beneficial effects, observed in mice after delivery of
mesoangioblasts in experimental models of tissue repair
(Sampaolesi et al., 2003, 2006; Galli et al., 2005; Galvez et al.,
2006). The secretion of MMP-2 and MMP-9 in their active
form by mesoangioblasts could also facilitate the HMGB-1-
dependent migration of these cells to sites of inflammation. We
propose that mesoangioblasts, experimentally delivered to the
vicinity of damaged tissues, could release active MMP-9 and
thereby support the activity of macrophages.
In A6 cultured cells, vesicle shedding was also evident at
low-oxygen tension, similar to that characteristic of mouse
tissues. This is important because after experimental injection
into the circulation, these cells reach areas of inflammation
where the oxygen tension is lower than that at which they are
usually grown in culture. Thus, although the vesicle production
we demonstrated was observed in vitro, it is reasonable to
suppose that mesoangioblasts also release vesicles in vivo. The
data presented here, however, do not preclude the possibility
that other tissue microenvironmental factors may modulate or
disrupt this process.
We conclude that the production of vesicles by
mesoangioblasts may be a mechanism for releasing signaling
molecules in a protected form. Although an analysis of the
protein profile of vesicles revealed a complex protein pattern,JOURNAL OF CELLULAR PHYSIOLOGYwe have clearly demonstrated that two types of proteins—
FGF-2 and MMPs—that are known to be important in tissue
repair are present in an active form. These findings suggest that
mesoangioblasts themselves, through the secretion of specific
paracrine signals and factors in membrane vesicles, make
damaged tissues more amenable to mesoangioblast cell
therapy.
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